Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

VJOncology

Internships: Growing the pool of recruitable talent, or cheap labour?

How 'try before you buy' can be an enormous help in medical communications

What makes the difference in the biosimilar battle?

The biosimilar market is set to get competitive but only players with a clear differentiation will succeed

National Institute for Health and Care Excellence NICE logo

NICE backs Lilly’s rheumatoid arthritis drug Olumiant

The drug will be used alongside methotrexate to treat adults with severe, active RA

Loss aversion

Healthcare's most important behavioural lesson

Daiichi Sankyo logo

Daiichi drug hits mark in shingles pain, but misses in other indications

ALDAY trial shows mirogabalin was unable to reduce pain for fibromyalgia patients

Lucid Partners grows its medical writing team

The past year has been the most successful for Lucid Group yet. They have celebrated their 10th year of business, launched their new Strategic Consultancy, won a Queen’s Award for...

Lucid Group Communications Limited

- PMLiVE

The Communiqué Awards at 20: Dennis O’Brien

Lucid's CEO on the Awards' enduring influence

Hall & Partners launch new consultancy OpenMind

Picks Jen Drexler to lead its new offering

- PMLiVE

Massive uncertainty is the new norm

How to make it work for your company

- PMLiVE

Biogen develops quantum computing-based app to speed drug discovery

Collaborates with Accenture and 1QBit in neurological diseases

AstraZeneca AZ

AZ takes Chi-Med’s kidney cancer drug into phase III

SAVOIR trial will compare Chi-Med’s savolitinib to Pfizer’s Sutent

- PMLiVE

Novartis gets first-line approval for Xalkori challenger in EU

Zykadia showed a 45% reduction in the risk of disease progression compared to chemo

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links